Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T21:46:19.438Z.
Calculation as of: 2026-10-06T21:46:19.438Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc6ba70d6a7a815a92143918ed9b9c2f02635c4477fd12c4733392629ce909df
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$82.53M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$82.59M
EV/EBIT Ratio
N/A
TTM Avg
12.93x
3Y Avg
47.97x
5Y Avg
47.97x
Market Cap
$84.13M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$79.61M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | $82.47M | N/A | N/A | N/A | N/A |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO)vs › | $82.53M | N/A | N/A | N/A | N/A |
| ProMIS Neurosciences, Inc. (PMN)vs › | $82.59M | N/A | 12.93x | 47.97x | 47.97x |
| LENSAR Inc (LNSR)vs › | $82.29M | N/A | N/A | N/A | N/A |
| MediciNova, Inc. (MNOV)vs › | $81.22M | N/A | N/A | N/A | N/A |
| Nutriband Inc. (NTRB)vs › | $81.20M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.13M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $80.30M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | N/A | N/A | N/A | N/A |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $85.86M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
